Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Since its launch in late March, Mounjaro sales have trebled. Winselow Tucker, president and general manager of Lilly in India ...

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

The manufacturer of Mounjaro has responded to dangerous hack that’s been doing the rounds on social media. Videos of people ...

Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Eli Lilly & Co. sees 60% sales increase for weight-loss drug in India, tapping into growing demand for anti-obesity solutions ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s ...